Click here if you are having trouble viewing this message.

International Women's Day is 8 March: Equality for Women is Progress for All
Inequity in life continues to place a disproportionate share of the HIV/AIDS burden on women, particularly in sub-Saharan Africa. IAVI is proud to work alongside thousands of women and men – scientists, clinicians, advocates, volunteers, educators – committed to developing an AIDS vaccine that can shift these odds.
Join the conversation: #women>AIDS.
News & Events
IAVI and Partners Initiate Early Clinical Study of New Strategy to Help Prevent HIV
Our newest Phase I clinical trial in the U.K. will examine a prototype candidate and a potential new method to prevent HIV infection with a vector carrying genetic instructions for producing the broadly neutralizing antibody (bNAb) PG9. Read more…

Exciting New Vaccine Design Approach Holds Promise for HIV
Researchers at The Scripps Research Institute (TSRI), with support from IAVI, successfully employed new "designer proteins" to create a vaccine that can elicit bNAbs against a significant cause of child mortality. The new approach holds promise for other challenging viruses, like HIV. Read more…

Disease Progression Data at CROI Pave Way for Understanding New Prevention Opportunities
At the annual Conference on Retroviruses and Opportunistic Infections (CROI), we showcased with our African partners data from Protocol C, an evaluation of disease progression in volunteers with recent HIV infections to help prepare for preventive vaccine trials. Findings from four countries could help advance important prevention opportunities such as early initiation of treatment for the newly infected.
Learn more about the conference

Research Progress, Work with Youth Among Highlights at ICASA 2013
At the 2013 International Conference on AIDS and STIs in Africa (ICASA), one of the largest African meetings on AIDS, we led or co-sponsored more than 10 events—from a skill-building seminar that explored advocacy in Africa and the importance of new prevention technologies for vulnerable groups like young people to a satellite session co-organized with UNAIDS demonstrating just how far we have come in the quest for an AIDS vaccine. Learn more about the conference…

Joint Collaboration on Research Preparedness a Focal Point for ICAAP11 in India
At the 11th International Congress on AIDS in Asia and the Pacific (ICAAP11), our presentation on the NARRIM project, a joint collaboration with the Indian Council for Medical Research, explored enhancing community research preparedness and cohort formation among vulnerable groups. We also joined with Dr. Ramesh Paranjape (Director of India's National AIDS Research Institute) and Anjali Gopalan (Founder & Executive Director, The NAZ Foundation Trust) to advocate for HIV vaccines and other promising prevention research in India.
Learn more about the conference

Alex Coutinho Becomes Chair, Eric Goosby and Lord Fowler Join IAVI Board
Dr. Alex Godwin Coutinho became Chair of the IAVI Board of Directors, and we welcomed as Board members U.S. Ambassador Eric Goosby and the Rt. Hon. the Lord Fowler of the U.K. IAVI's Board members represent more than 10 countries with distinguished experience in healthcare, finance, vaccinology, clinical research, international development and academia.

In Memoriam: Dr. Reinhard Kurth, Former Scientific Advisory Committee Chair
We mourn the passing of Dr. Reinhard Kurth, a leading biomedical scientist who served as a Board member and Chair of the IAVI Scientific Advisory Committee from 2010 to 2013.
Funding Updates
A Word of Thanks for Our Donors
We continue to express our deep appreciation for the support and commitment of all our public, private and individual donors across the world. Their steadfast support, particularly during these challenging financial times, is essential to ensuring our continued progress toward developing an AIDS vaccine.

Norway Renews its Commitment for the Next Three Years
In December 2013, we signed a new grant with the Norwegian Government, through the
Norwegian Agency for Development Cooperation (Norad), for NOK6 million (US$1 million) in unrestricted funding per year for three years. Norwegian investments have helped us build a comprehensive portfolio of AIDS vaccine approaches and candidates since 2001. This renewed support from Norad will allow us to continue bringing together expertise from different sectors and regions of the world to collaboratively design and evaluate novel vaccine candidates.

RWJF Grant to Help Catalyze a Human Vaccines Project
With a US$378,000 grant from the Robert Wood Johnson Foundation, we hosted the first in a series of meetings bringing together international scientists and public health experts to leverage technological advances and accelerate the development of new vaccines against AIDS, tuberculosis, malaria and other major diseases.

EMMES Corporation Renews Commitment to IAVI
We gratefully acknowledge
The EMMES Corporation for its renewed commitment of in-kind support for 2014, marking the fourth year as an IAVI donor. The EMMES Corporation provides the full range of Contract Research Organization expertise necessary to conduct clinical research with a firm scientific basis that is fully compliant with national and international regulatory guidelines. This expertise has been essential to the success of our clinical work and data management.

G-finder Report: The Need for Increased Product Development Support for Neglected Diseases
The latest edition of the
G-finder Report, tracking global R&D investment for 31 neglected diseases, shows that funding for product development declined in the past three years, even as investment overall remained virtually flat. At a launch event, we joined representatives from the Bill & Melinda Gates Foundation, Deutsche Stiftung Weltbevölkerung, Policy Cures and the German Parliament to emphasize the need for increased funding from nations like Germany, which remains committed to product development and PDP funding. 

Video Blogger Raises $25,000 for AIDS Vaccine R&D
Armed only with a webcam, video blogger
Devchelle2 has raised more than US$25,000 for IAVI through live blog events since 2011. From 29-30 March, Devchelle2 will take to the blogosphere once again to host a 36-hour event benefitting IAVI. We are incredibly grateful to all individuals who support AIDS vaccine research through fundraising and personal donations.
IAVI & AIDS Vaccines in the News
Breakthrough Vaccines (; Will New Approaches for AIDS Vaccine Design Lead Us Into a New Era for Vaccinology? ( Our Chief Scientific Officer Wayne Koff on what collaborative research could mean for AIDS and other major infectious diseases.

"Hot" Papers Point to Key Research on HIV/AIDS ( We are among the "hottest" sources for HIV/AIDS research.

Do We Still Need an AIDS Vaccine? (New England Journal of Medicine): Anthony Fauci of the U.S. National Institute of Allergy and Infectious Diseases offers eloquent support for an AIDS vaccine based on a
commentary in The New England Journal of Medicine.

Carrying on Work of Nelson Mandela ( We are one of many organizations continuing to work toward Mandela's vision.

Positive Signals in Indian Research on HIV Vaccines (The Hindu): Vaccine R&D insights from IAVI colleagues and the HIV Vaccine Translational Research Laboratory.

Click here for more coverage of our work around the world.

IAVI consistently demonstrates efficient management of resources, earning high marks from Charity Navigator in accountability and transparency.

Copyright © 2014 International AIDS Vaccine Initiative. All rights reserved. International AIDS Vaccine Initiative,
IAVI and the IAVI logo are trademarks of the International AIDS Vaccine Initiative, Inc.

International AIDS Vaccine Initiative
Click here if you don't wish to receive these messages in the future.
Click . if you don't wish to receive these messages in the future.